Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A3 adenosine receptors in cardiomyoyctes.

Wan TC, Tampo A, Kwok WM, Auchampach JA.

Biochem Pharmacol. 2019 May;163:21-31. doi: 10.1016/j.bcp.2019.01.022. Epub 2019 Jan 30.

PMID:
30710517
2.

Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.

Tosh DK, Rao H, Bitant A, Salmaso V, Mannes P, Lieberman DI, Vaughan KL, Mattison JA, Rothwell AC, Auchampach JA, Ciancetta A, Liu N, Cui Z, Gao ZG, Reitman ML, Gavrilova O, Jacobson KA.

J Med Chem. 2019 Feb 14;62(3):1502-1522. doi: 10.1021/acs.jmedchem.8b01662. Epub 2019 Jan 3.

PMID:
30605331
3.

Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists.

Yu J, Mannes P, Jung YH, Ciancetta A, Bitant A, Lieberman DI, Khaznadar S, Auchampach JA, Gao ZG, Jacobson KA.

Medchemcomm. 2018 Oct 18;9(11):1920-1932. doi: 10.1039/c8md00317c. eCollection 2018 Nov 1.

PMID:
30568760
4.

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists.

Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA.

ACS Omega. 2018 Oct 31;3(10):12658-12678. doi: 10.1021/acsomega.8b01237. Epub 2018 Oct 4.

5.

IL-13 promotes in vivo neonatal cardiomyocyte cell cycle activity and heart regeneration.

Wodsedalek DJ, Paddock SJ, Wan TC, Auchampach JA, Kenarsary A, Tsaih SW, Flister MJ, O'Meara CC.

Am J Physiol Heart Circ Physiol. 2019 Jan 1;316(1):H24-H34. doi: 10.1152/ajpheart.00521.2018. Epub 2018 Oct 19.

PMID:
30339498
6.

Activation of adenosine A2A or A2B receptors causes hypothermia in mice.

Carlin JL, Jain S, Duroux R, Suresh RR, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML.

Neuropharmacology. 2018 Sep 1;139:268-278. doi: 10.1016/j.neuropharm.2018.02.035. Epub 2018 Mar 13.

PMID:
29548686
7.

Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.

Duroux R, Ciancetta A, Mannes P, Yu J, Boyapati S, Gizewski E, Yous S, Ciruela F, Auchampach JA, Gao ZG, Jacobson KA.

Medchemcomm. 2017 Aug 1;8(8):1659-1667. doi: 10.1039/C7MD00247E. Epub 2017 Jun 22.

8.

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators.

Du L, Gao ZG, Paoletta S, Wan TC, Gizewski ET, Barbour S, van Veldhoven JPD, IJzerman AP, Jacobson KA, Auchampach JA.

Purinergic Signal. 2018 Mar;14(1):59-71. doi: 10.1007/s11302-017-9592-1. Epub 2017 Nov 23.

9.

Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.

Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2017 Apr 13;60(7):3109-3123. doi: 10.1021/acs.jmedchem.7b00141. Epub 2017 Mar 20.

10.

Hypothermia in mouse is caused by adenosine A1 and A3 receptor agonists and AMP via three distinct mechanisms.

Carlin JL, Jain S, Gizewski E, Wan TC, Tosh DK, Xiao C, Auchampach JA, Jacobson KA, Gavrilova O, Reitman ML.

Neuropharmacology. 2017 Mar 1;114:101-113. doi: 10.1016/j.neuropharm.2016.11.026. Epub 2016 Nov 30.

11.

Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.

Tosh DK, Ciancetta A, Warnick E, O'Connor R, Chen Z, Gizewski E, Crane S, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2016 Apr 14;59(7):3249-63. doi: 10.1021/acs.jmedchem.5b01998. Epub 2016 Feb 18.

12.

Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension.

Nayak S, Khan MA, Wan TC, Pei H, Linden J, Dwinell MR, Geurts AM, Imig JD, Auchampach JA.

Purinergic Signal. 2015 Dec;11(4):519-31. doi: 10.1007/s11302-015-9470-7. Epub 2015 Sep 18.

13.

Structure-Based Design, Synthesis by Click Chemistry and in Vivo Activity of Highly Selective A3 Adenosine Receptor Agonists.

Tosh DK, Paoletta S, Chen Z, Crane S, Lloyd J, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA.

Medchemcomm. 2015;6:555-563.

14.

Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.

Tosh DK, Crane S, Chen Z, Paoletta S, Gao ZG, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.

ACS Med Chem Lett. 2015 May 20;6(7):804-8. doi: 10.1021/acsmedchemlett.5b00150. eCollection 2015 Jul 9.

15.

In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.

Tosh DK, Finley A, Paoletta S, Moss SM, Gao ZG, Gizewski ET, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2014 Dec 11;57(23):9901-14. doi: 10.1021/jm501021n. Epub 2014 Nov 25.

16.

Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure.

Lakshmikanthan S, Zieba BJ, Ge ZD, Momotani K, Zheng X, Lund H, Artamonov MV, Maas JE, Szabo A, Zhang DX, Auchampach JA, Mattson DL, Somlyo AV, Chrzanowska-Wodnicka M.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1486-94. doi: 10.1161/ATVBAHA.114.303678. Epub 2014 May 1.

17.

Effect of human 15-lipoxygenase-1 metabolites on vascular function in mouse mesenteric arteries and hearts.

Kriska T, Cepura C, Siangjong L, Wan TC, Auchampach JA, Shaish A, Haratz D, Kumar G, Falck JR, Gauthier KM, Campbell WB.

Prostaglandins Other Lipid Mediat. 2013 Oct;106:8-15. doi: 10.1016/j.prostaglandins.2013.07.002. Epub 2013 Jul 16.

18.

Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.

Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2013 Jul 25;56(14):5949-63. doi: 10.1021/jm4007966. Epub 2013 Jul 3.

19.

An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering.

Ntantie E, Gonyo P, Lorimer EL, Hauser AD, Schuld N, McAllister D, Kalyanaraman B, Dwinell MB, Auchampach JA, Williams CL.

Sci Signal. 2013 May 28;6(277):ra39. doi: 10.1126/scisignal.2003374.

20.

Characterization by flow cytometry of fluorescent, selective agonist probes of the A(3) adenosine receptor.

Kozma E, Gizewski ET, Tosh DK, Squarcialupi L, Auchampach JA, Jacobson KA.

Biochem Pharmacol. 2013 Apr 15;85(8):1171-81. doi: 10.1016/j.bcp.2013.01.021. Epub 2013 Jan 31.

21.

Adenosine A1 receptors heterodimerize with β1- and β2-adrenergic receptors creating novel receptor complexes with altered G protein coupling and signaling.

Chandrasekera PC, Wan TC, Gizewski ET, Auchampach JA, Lasley RD.

Cell Signal. 2013 Apr;25(4):736-42. doi: 10.1016/j.cellsig.2012.12.022. Epub 2013 Jan 3.

22.

Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.

Tosh DK, Deflorian F, Phan K, Gao ZG, Wan TC, Gizewski E, Auchampach JA, Jacobson KA.

J Med Chem. 2012 May 24;55(10):4847-60. doi: 10.1021/jm300396n. Epub 2012 May 16.

23.

Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.

Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA.

BMC Pharmacol. 2011 Oct 31;11:11. doi: 10.1186/1471-2210-11-11.

24.

Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.

Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA.

J Pharmacol Exp Ther. 2012 Jan;340(1):210-7. doi: 10.1124/jpet.111.187559. Epub 2011 Oct 19.

25.

A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils.

van der Hoeven D, Wan TC, Gizewski ET, Kreckler LM, Maas JE, Van Orman J, Ravid K, Auchampach JA.

J Pharmacol Exp Ther. 2011 Sep;338(3):1004-12. doi: 10.1124/jpet.111.181792. Epub 2011 Jun 21.

26.

Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury.

Xiang SY, Ye LL, Duan LL, Liu LH, Ge ZD, Auchampach JA, Gross GJ, Duan DD.

Acta Pharmacol Sin. 2011 Jun;32(6):824-33. doi: 10.1038/aps.2011.61.

27.

Are we putting too much stock in mice?

Auchampach JA, Maas JE, Wan TC, Figler RA, Gross GJ.

J Mol Cell Cardiol. 2011 Mar;50(3):584-5. doi: 10.1016/j.yjmcc.2010.11.016. Epub 2010 Dec 1. No abstract available.

PMID:
21129379
28.

Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor.

Maas JE, Wan TC, Figler RA, Gross GJ, Auchampach JA.

J Mol Cell Cardiol. 2010 Nov;49(5):886-93. doi: 10.1016/j.yjmcc.2010.08.015. Epub 2010 Aug 24.

29.

Activation of the A(3) adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils.

van der Hoeven D, Gizewski ET, Auchampach JA.

Biochem Pharmacol. 2010 Jun 1;79(11):1667-73. doi: 10.1016/j.bcp.2010.02.002. Epub 2010 Feb 10.

30.

A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells.

Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA.

J Mol Cell Cardiol. 2010 Aug;49(2):280-6. doi: 10.1016/j.yjmcc.2010.01.018. Epub 2010 Feb 2.

31.

Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism.

Ge ZD, Pravdic D, Bienengraeber M, Pratt PF Jr, Auchampach JA, Gross GJ, Kersten JR, Warltier DC.

Anesthesiology. 2010 Jan;112(1):73-85. doi: 10.1097/ALN.0b013e3181c4a607.

32.

Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor.

Auchampach JA, Gizewski ET, Wan TC, de Castro S, Brown GG Jr, Jacobson KA.

Biochem Pharmacol. 2010 Apr 1;79(7):967-73. doi: 10.1016/j.bcp.2009.11.009. Epub 2009 Nov 14.

33.
34.

Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.

Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE.

J Pharmacol Exp Ther. 2009 Apr;329(1):2-13. doi: 10.1124/jpet.108.148270. Epub 2009 Jan 13.

35.

Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor.

Liou GI, Auchampach JA, Hillard CJ, Zhu G, Yousufzai B, Mian S, Khan S, Khalifa Y.

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5526-31. doi: 10.1167/iovs.08-2196. Epub 2008 Jul 18.

36.

Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils.

van der Hoeven D, Wan TC, Auchampach JA.

Mol Pharmacol. 2008 Sep;74(3):685-96. doi: 10.1124/mol.108.048066. Epub 2008 Jun 26.

37.

Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.

Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, Jacobson KA.

Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9. doi: 10.1016/j.bmcl.2008.04.001. Epub 2008 Apr 4.

38.

Adenosine receptors and angiogenesis.

Auchampach JA.

Circ Res. 2007 Nov 26;101(11):1075-7. Review. No abstract available.

39.

The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.

Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA.

J Pharmacol Exp Ther. 2008 Jan;324(1):234-43. Epub 2007 Sep 28.

40.

Reperfusion injury: does it exist?

Gross GJ, Auchampach JA.

J Mol Cell Cardiol. 2007 Jan;42(1):12-8. Epub 2006 Oct 27. Review.

41.

Improved cardiac function in infarcted mice after treatment with pluripotent embryonic stem cells.

Nelson TJ, Ge ZD, Van Orman J, Barron M, Rudy-Reil D, Hacker TA, Misra R, Duncan SA, Auchampach JA, Lough JW.

Anat Rec A Discov Mol Cell Evol Biol. 2006 Nov;288(11):1216-24.

42.

Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.

Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, Auchampach JA.

J Pharmacol Exp Ther. 2006 Dec;319(3):1200-10. Epub 2006 Sep 19.

PMID:
16985166
43.

Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.

Carrier EJ, Auchampach JA, Hillard CJ.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7895-900. Epub 2006 May 3.

44.

Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor.

Kreckler LM, Wan TC, Ge ZD, Auchampach JA.

J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9.

PMID:
16339914
45.

Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway.

Gross ER, Peart JN, Hsu AK, Auchampach JA, Gross GJ.

Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2744-9. Epub 2005 Jan 14.

46.

Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors.

Fabritz L, Kirchhof P, Fortmüller L, Auchampach JA, Baba HA, Breithardt G, Neumann J, Boknik P, Schmitz W.

Cardiovasc Res. 2004 Jun 1;62(3):500-8.

47.

Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs.

Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ.

J Pharmacol Exp Ther. 2004 Mar;308(3):846-56. Epub 2003 Nov 21.

PMID:
14634049
48.

A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.

Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ.

Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H607-13. Epub 2003 Apr 10.

49.

Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists.

Ge ZD, Auchampach JA, Piper GM, Gross GJ.

J Cardiovasc Pharmacol. 2003 Mar;41(3):481-8.

PMID:
12605028
50.

Therapeutic receptor targets of ischemic preconditioning.

Fryer RM, Auchampach JA, Gross GJ.

Cardiovasc Res. 2002 Aug 15;55(3):520-5. Review.

Supplemental Content

Loading ...
Support Center